Enjoy complimentary customisation on priority with our Enterprise License!
The cancer supportive care market is estimated to grow by USD 6.56 billion at a CAGR of 4.62% between 2022 and 2027. The growing prevalence of cancer cases worldwide is increasing the demand for effective treatments and supportive care options. Many side effects associated with cancer treatment, such as nausea, pain, and fatigue, create a need for supportive care products to improve patients' quality of life. The untapped potential in developing countries presents opportunities for market expansion, as these regions seek to improve access to cancer care and treatment options. It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
View the Bestselling Market Report sample Instantly
This market report extensively covers market segmentation by therapeutic area (chemotherapy-induced anemia, chemotherapy-induced neutropenia, cancer pain, CINV, and others), distribution channel (hospitals pharmacies, drug stores and retail pharmacies, and online providers), and geography (North America, Europe, Asia, and Rest Of World (ROW)).
The market share growth of the chemotherapy-induced anemia segment will be significant during the forecast period. Anemia is a condition that develops when the blood lacks the required amount of healthy red blood cells or hemoglobin. Anemia is one of the most common types of side effects faced by individuals undergoing treatment. Almost all individuals going through chemotherapy suffer mild anemia, and more than three-fourths of them develop more severe problems. As these cases are rising in developing countries as well, the higher adoption rate of chemotherapy will increase the demand for drugs indicated for chemotherapy-induced anemia, thereby driving market growth.
Get a glance at the market contribution of various segments Request a PDF Sample
The chemotherapy-induced anemia segment was valued at USD 6.13 billion in 2017. Cancer or chemotherapeutic drugs can cause anemia in an individual. Cancer suppresses erythropoiesis, leading to anemia. Chemotherapy targets fast-dividing cells as well as healthy cells in the body. The cells in the bone marrow are highly sensitive to chemotherapy, resulting in the decreased production of red blood cells in the body. As the destruction of bone marrow is certain post-chemotherapy, the cases of anemia will rise in developed countries as well, thereby driving market growth.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
North America holds the largest share of the market owing to the huge investments made in the oncology sector in the US. The US dominates the regional market and acts as the major revenue generator, followed by Canada. Huge investments in the pharmaceutical industry, specifically the oncology sector, and the presence of pharmaceutical giants in the region are some of the major factors backing the dominance of the US in the region as well as globally. This is one of the most common chronic diseases in the US. Also, in every 100,000 population, 436 new cancer cases were reported, and about 156 died of cancer in the country in the same year. Thus, with the growing incidences of cancer, companies will invest in extensive research to develop effective drugs for the treatment of several cancers. As these drugs are associated with several side effects, the demand is expected to increase in the region during the forecast period.
The market encompasses a range of treatments and medications aimed at improving the quality of life for cancer patients undergoing chemotherapy and other treatments. These include Granulocyte Colony-Stimulating Factors (GCSFs) to boost white blood cell production, Antiemetics to manage nausea and vomiting, and supportive care drugs to address various side effects like anemia and hair loss. Organizations like the National Cancer Institute and the American Cancer Society play key roles in advancing research and promoting access to these treatments. As the cancer prevalence increases, particularly among the geriatric population, there's a growing focus on supportive care to enhance treatment outcomes and mitigate adverse effects. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The growing prevalence of cancer cases is notably driving market growth. This is increasingly becoming a significant health concern worldwide, leading to higher mortality rates. Genetic mutations, environmental factors like tobacco smoking and pollution, and changing dietary habits are major contributors to the development. Understanding these factors is crucial for developing effective prevention and treatment strategies. Additionally, managing these involves considerations such as new patient E&M visits, current patient E&M visits, the use of biosimilars and generic medications, and the use of ESA (erythropoiesis-stimulating agents) when appropriate. The growing prevalence of these factors has directly contributed to the rising incidence, making it the second leading cause of death globally. It's crucial to register cancer diagnoses, treatment rates, and mortality to understand trends in a country. Medical researchers require current cancer-related data to monitor trends and investigate potential causes. Healthcare providers need this data to make informed decisions about equipment and medication procurement for treatment and to develop awareness and prevention programs. The increasing incidence and prevalence of cancer are expected to drive demand, leading to market growth in this area.
The advent of biosimilars in cancer-associated treatment is the primary trend in the market. The growing demand for quality care has led to the increased use of erythropoietin drugs for the treatment of chemotherapy-induced anaemia. The majority of countries are under pressure to address this demand without increasing healthcare expenditure. Biosimilars will likely play a prominent role in this scenario, as, unlike generic drugs, they have the same active pharmaceutical ingredients as their originator biological compounds. Biosimilars are less expensive than biologics, thereby increasing accessibility. The patent expiry of biologics has led to the emergence of their biosimilars.
Epoetin alfa BS injection by JCR Pharmaceuticals and Kissei Pharmaceutical is a biosimilar version of Epoetin alfa. JCR Pharmaceuticals is also developing JR-013-sc Erythropoietin (which is under the Phase I stage of development) and JR-131 Darbopoietin (which is under the preclinical stage of development); both are of recombinant DNA origin. In addition, low-cost biosimilars are expected to affect the prices of branded drugs, thereby increasing the accessibility of drugs.
The increasing preference for targeted therapies over chemotherapy drugs will hinder the growth prospects of the market. As there is an increased need to target specific molecules that are responsible for the growth of cancer, companies are focusing on the development of targeted therapies, which have higher specificity than traditional chemotherapy drugs. Also, as chemotherapy drugs are associated with several side effects, researchers are conducting extensive R&D activities to better understand the disease's etiology and develop novel treatments.
companies are investing huge amounts to obtain approval for their cancer drugs. For instance, Boston-based Blueprint Medicines received clearance from the US FDA for its genetically targeted cancer therapy, Ayvakit, which is used for the treatment of gastrointestinal stromal tumours. Such market dynamics may hamper the market growth.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Market Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Amgen Inc. - The company offers cancer-supportive care products such as Neulasta and Aranesp. This segment focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics.
The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
The market is driven by the rising prevalence of breast cancer, colorectal cancer, lung cancer, and liver cancer, necessitating effective treatments to manage symptoms and side effects. This market encompasses a range of drugs, including erythropoiesis-stimulating agents (ESA) and granulocyte colony-stimulating factors (G-CSFs), designed to address issues like nausea and vomiting control and infection prevention. With a focus on patient-centric care and personalized medicine, new drugs are continuously being developed and tested in clinical trials to improve outcomes. The market is also influenced by regulatory frameworks and reimbursement policies, particularly from organizations like the Centers for Medicare and Medicaid Innovation (CMMI) and the World Health Organization (WHO). Increasing convenience through channels like e-commerce and online pharmacies is also shaping the market landscape.
The market is vital in addressing the complex needs of cancer patients, offering bisphosphonates for managing bone complications and G-CSFs (granulocyte colony-stimulating factors) to boost white blood cell production post-chemotherapy. These drugs are crucial in managing symptoms and side effects, especially for patients with metastatic colorectal cancer and prostate cancer. The market is supported by various distribution channels, including hospital pharmacies, drug stores & retail pharmacies, and online pharmacies, ensuring accessibility to these essential medications. The market plays a crucial role in addressing the diverse needs of cancer patients. With a focus on managing symptoms and side effects, it offers a range of drugs and treatments. This market encompasses various aspects, including distribution channels like hospital and Retail pharmacy, as well as Online pharmacy, ensuring easy access to medications. Cell research advancements drive the development of innovative therapies, while the market navigates challenges such as economic recessions. It remains pivotal in supporting patients and improving their quality of life.
Market Scope |
|
Report Coverage |
Details |
Page number |
175 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 4.62% |
Market growth 2023-2027 |
USD 6.56 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
3.92 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 39% |
Key countries |
US, Canada, UK, Germany, and China |
Competitive landscape |
Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Acacia Pharma Group Plc, Amgen Inc., Baxter International Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Johnson and Johnson, Kyowa Kirin Co. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, RELIEF THERAPEUTICS Holding SA, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. |
Market dynamics |
Parent market analysis, Market Forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.